13 research outputs found

    The cytotoxic mechanisms of disulfiram and copper(ii) in cancer cells

    Get PDF
    The anticancer activity of disulfiram (DS) is copper(II) (Cu)-depen-dent. This study investigated the anticancer mechanisms of DS/Cuusingin vitrocytotoxicity and metabolic kinetic analysis. Our studyindicates that DS/Cu targets cancer cells by the combination oftwo types of actions: (1) instant killing executed by DS/Cu reactiongenerated reactive oxygen species; (2) delayed cytotoxicity intro-duced by the end product, DDC-Cu. Nanoencapsulation of DSmight shed light on repositioning of DS into cancer treatment

    Review of solid–liquid phase change materials and their encapsulation technologies

    Get PDF
    Various types of solid–liquid phase change materials (PCMs) have been reviewed for thermal energy storage applications. The review has shown that organic solid–liquid PCMs have much more advantages and capabilities than inorganic PCMs but do possess low thermal conductivity and density as well as being flammable. Inorganic PCMs possess higher heat storage capacities and conductivities, cheaper and readily available as well as being non-flammable, but do experience supercooling and phase segregation problems during phase change process. The review has also shown that eutectic PCMs have unique advantage since their melting points can be adjusted. In addition, they have relatively high thermal conductivity and density but they possess low latent and specific heat capacities. Encapsulation technologies and shell materials have also been examined and limitations established. The morphology of particles was identified as a key influencing factor on the thermal and chemical stability and the mechanical strength of encapsulated PCMs. In general, in-situ polymerization method appears to offer the best technological approach in terms of encapsulation efficiency and structural integrity of core material. There is however the need for the development of enhancement methods and standardization of testing procedures for microencapsulated PCMs

    A crowdsourced analysis to identify ab initio molecular signatures predictive of susceptibility to viral infection

    Get PDF
    The response to respiratory viruses varies substantially between individuals, and there are currently no known molecular predictors from the early stages of infection. Here we conduct a community-based analysis to determine whether pre- or early post-exposure molecular factors could predict physiologic responses to viral exposure. Using peripheral blood gene expression profiles collected from healthy subjects prior to exposure to one of four respiratory viruses (H1N1, H3N2, Rhinovirus, and RSV), as well as up to 24 h following exposure, we find that it is possible to construct models predictive of symptomatic response using profiles even prior to viral exposure. Analysis of predictive gene features reveal little overlap among models; however, in aggregate, these genes are enriched for common pathways. Heme metabolism, the most significantly enriched pathway, is associated with a higher risk of developing symptoms following viral exposure. This study demonstrates that pre-exposure molecular predictors can be identified and improves our understanding of the mechanisms of response to respiratory viruses

    Perovskite/Silicon Tandem Solar Cells: Choice of Bottom Devices and Recombination Layers

    No full text
    Perovskite/silicon tandem solar cells have been intensively studied in recent years, and their efficiencies have rapidly increased owing to the numerous efforts in this field. A question about which type of silicon solar cell is the most suitable subcell in tandem devices emerges. Herein, three attractive silicon solar cells are summarized, including passivated-emitter rear-cell (PERC), tunnel oxide passivated contact (TOPCon), and heterojunction (HJT) cells. Their structures and features are elucidated for a clear understanding of the mechanism and potential of optimum performance. Moreover, the characteristics and performance of perovskite/ silicon tandem cells with PERC, TOPCon, and HJT subcells are contrasted and discussed. The significant contribution of the passivation layer and structure design on both sides to photovoltaic properties of tandem devices is emphasized. Especially, the recombination layer between two subcells is analyzed in depth in terms of material chemistry, light absorption, and charge transport with a review on preparing the optimized structure

    Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3 years

    No full text
    Abstract Background The purpose of this study was to evaluate the efficacy of denosumab or zoledronic acid (ZA) using symptomatic skeletal events (SSEs) as the primary endpoint in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer. Methods Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer receiving subcutaneous denosumab 120 mg Q4W, or intravenous ZA 4 mg Q4W until the primary analysis cut-off date were retrospectively analysed in the Hong Kong Practice-Based Cancer Research Center(HKCRC) from March 2011 to March 2013. The time to first on-study SSE that was assessed either clinically or through routine radiographic scans was the primary endpoint. Results 242 patients received denosumab or ZA treatment (n = 120, mean age of 64.9 years (SD 3.01) and n = 122, 65.4 years (3.44), respectively). The median times to first on-study SSE were 14.7 months (12.9–45.6) and 11.7 months (9.9–45.6) for denosumab and ZA, respectively (hazard ratio, HR 0.44, 95% CI 0.71–2.95; p = 0·0002). Compared with the ZA group, denosumab-treated patients had a significantly delayed time to first SSE (HR 0.65 [95% CI 0.29–1.45], p < 0.0001). An increased incidence of SSE was found in the 16-month follow-up with rates of 2.1 and 10.7% for denosumab and ZA, respectively (P = 0.033). The difference persisted with time with rates of 8.3 and 17.2% at the final follow-up, respectively (P < 0.05). Conclusion In postmenopausal women aged ≥60 years with oestrogen-receptor-positive advanced breast cancer, denosumab significantly reduced the risk of developing SSEs compared with ZA. The findings of this pilot trial justify a larger study to determine whether the result is more generally applicable to a broader population
    corecore